这番言论在网络引发多元讨论。有网友表示， "绝不是泛指所有人，活到120岁只是权势的追求。尤其在步入老龄化社会的当下，对于普通人来说，身体机能老化后，活着只是一种痛苦，对于子女来说也 是一种沉重的负担。"反映了公众对健康长寿背后社会负担的担忧。 "他意思是说，有钱人都可以活到120岁吧？"这种质疑，指向了医疗资源可及性和技术普惠性的现实命题。 "别人的脸，别人的装扮，别人的衣着，跟你们到底是有啥关系啊，咸吃萝卜淡操心。你的本事超过她，再去评价她。" 近日，华熙集团董事长、华熙生物董事长兼总裁赵燕关于"让人能够健康活到超过120岁"的言论再度引发热议。在企业家之夜活动中，赵燕对此前在可持续 全球领导者大会上的发言做出进一步回应，阐述了她对科技改变人类寿命的展望。 此前，赵燕在可持续全球领导者大会上提出"让人能够健康，能蹦能跳，能吃能睡的活到超过120岁"的观点，迅速成为网络焦点。此次在企业家之夜，她再 次回应称："未来的十年，由于科技的发展，重大疾病将要被解决掉，现在我们认为的这些慢性病，什么高血压、高血脂、高血糖，什么高尿酸、阿尔兹海 默症，甚至肿瘤，我是认为在我们这个领域的努力下，是能攻克的啊。只要大家能够 ...

南方财经1月30日电，华熙生物董事长赵燕在"为中国经济点赞——企业家之夜"活动上表示，2026年将 成为AI真正进入华熙生物的元年。她介绍，AI将全面融入企业管理与业务运营，未来公司或将出现上 百个硅基智能体，不仅实现对"碳基人"的管理优化，更将贯穿各业务场景——面向C端提供消费者专家 服务、助力内容生成，在生产环节对接机器人提升效率，推动产业逻辑重塑与效率跃升。业务布局上， 华熙生物将重点聚焦两大核心方向，即衰老的干预与组织的再生，依托糖生物学、合成生物学等底层技 术，深耕大健康领域。（21世纪经济报道） ...

赵燕表示："我觉得作为我们企业来说，最大的收获就是从单点能力的积蓄到了系统性能力的沉淀成 型，尤其是我们打通了生命健康、情绪价值和城市生活方式的融合。" "我们是全球第一个将一个生物科技公司的科技生命消费品的品牌去冠名了两地。"赵燕指出，将生命科 技和我们的现代生活方式、情绪价值结合在一起的目的都是为了大家来打造一种新的一种生活方式，使 大家不要认为科技都是高高在上的，它是走进了我们的生活，就在我们的身边，实际上是时时刻刻在关 注着大家。我觉得我们做事的最终的目标都是为了让人能够有质量的活得长，要健康美丽才能快乐。这 是我觉得2025年对我们来说是最重要的一年。真正的打通了从科技然后走向生活，让大众能够在身边能 感知得到。 专题：为中国经济点赞——企业家之夜2025盛典 "为中国经济点赞——企业家之夜"于1月29日在北京举行。回忆2025，展望2026，华熙国际投资集团有 限公司董事长、华熙生物科技股份有限公司董事长兼总裁赵燕指出，2025年是一个充满挑战但是也蛮有 收获的一年。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 ...

专题：为中国经济点赞——企业家之夜2025盛典 "为中国经济点赞——企业家之夜"于1月29日在北京举行。回忆2025，展望2026，华熙国际投资集团有 限公司董事长、华熙生物科技股份有限公司董事长兼总裁赵燕指出，2025年是一个充满挑战但是也蛮有 收获的一年。 赵燕表示："我觉得作为我们企业来说，最大的收获就是从单点能力的积蓄到了系统性能力的沉淀成 型，尤其是我们打通了生命健康、情绪价值和城市生活方式的融合。" "我们是全球第一个将一个生物科技公司的科技生命消费品的品牌去冠名了两地。"赵燕指出，将生命科 技和我们的现代生活方式、情绪价值结合在一起的目的都是为了大家来打造一种新的一种生活方式，使 大家不要认为科技都是高高在上的，它是走进了我们的生活，就在我们的身边，实际上是时时刻刻在关 注着大家。我觉得我们做事的最终目标都是为了让人能够有质量的活得长，要健康美丽才能快乐。这是 我觉得2025年对我们来说是最重要的一年。真正的打通了从科技然后走向生活，让大众能够在身边能感 知得到。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 ...

Core Insights - The medical beauty sector experienced a rise of 2.96% on January 29, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Beauty Sector Performance - Ai Meike (300896) closed at 144.38, with a gain of 4.53%, trading volume of 56,700 shares, and a transaction value of 803 million [1] - Huaxi Biological (688363) closed at 46.31, up 1.47%, with a trading volume of 45,900 shares and a transaction value of 211 million [1] - Jinbo Biological (920982) closed at 226.88, up 1.35%, with a trading volume of 8,287 shares and a transaction value of 1.86 billion [1] - ST Meigu (000615) closed at 3.13, down 1.26%, with a trading volume of 103,100 shares and a transaction value of 32.32 million [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 105 million from main funds, while retail investors experienced a net outflow of 33.44 million [1] - Ai Meike had a main fund net inflow of 103 million, representing 12.77%, with retail outflows of 38.71 million [2] - Huaxi Biological had a main fund net inflow of 10.25 million, representing 4.86%, with retail outflows of 1.15 million [2] - Jinbo Biological had a main fund net inflow of 9.45 million, representing 5.09%, with retail inflows of 1.25 million [2] - ST Meigu had a main fund net outflow of 7.90 million, representing -24.43%, with retail inflows of 4.02 million [2]

作为生物制造领域的明星企业，华熙生物横跨活性物、医药医美、功能性护肤品和食品等众多赛道。过 去一年，华熙生物一直处于聚光灯下。 在政协北京市第十四届委员会第四次会议期间，来自经济界的市政协委员、华熙生物董事长赵燕围绕生 物制造产业发展、科技成果转化以及AI与产业融合等话题，接受了北京商报记者的专访。 而面对AI时代加速到来，赵燕表示，对于生物制造行业，AI不光是赋能，更是一个产业逻辑的重塑。 未来的企业能否存活，关键在于能否真正拥抱AI。要成为幸存者，企业必须重塑自身的业务逻辑与组 织架构，并配备相应的人才。 未来的团队中，管理者的能力将体现在如何管理两类人：一类是AI智能体，另一类是具有AI原生态思 维、善于运用AI的人。 与此同时，AI也拉近了我们与欧美在生物科技领域的距离。过去在从0到1的原始创新阶段，中国与发 达国家仍存在一定差距，但AI的到来实现了某种程度的"平权化"，重塑了创新逻辑。她坚信，只要在这 个时代"被重塑"，就能带来超预期的增长。 北京商报记者 陶凤 丁宁 随着透明质酸等成熟医美生物材料的市场竞争加剧，头部企业的技术积累与长期发展路径备受关注。与 此同时，各类再生材料等新兴赛道崛起，面对 ...

Market Overview - The medical beauty sector experienced a decline of 1.57% on January 28, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - *ST Meigu closed at 3.17, down 0.63% with a trading volume of 66,700 shares and a turnover of 21.20 million yuan [1] - Aimeike closed at 138.12, down 1.56% with a trading volume of 29,800 shares and a turnover of 413 million yuan [1] - Huaxi Biological closed at 45.64, down 1.70% with a trading volume of 28,800 shares and a turnover of 13.20 million yuan [1] - Jinbo Biological closed at 223.85, down 1.97% with a trading volume of 7,323 shares and a turnover of 165 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 49.81 million yuan from main funds, while retail investors had a net inflow of 55.20 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 1.98 million yuan, retail net inflow of 1.61 million yuan [2] - Huaxi Biological: Main funds net outflow of 9.06 million yuan, retail net inflow of 3.16 million yuan [2] - Jinbo Biological: Main funds net outflow of 25.03 million yuan, retail net inflow of 0.38 million yuan [2] - Aimeike: Main funds net outflow of 38.77 million yuan, retail net inflow of 50.43 million yuan [2]

| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 起張 | 华熙牛物青事长 | | 3 | 严建亚 | 巨子生物青事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷董事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物董事长 | | 8 | 前熔 | 美年健康董事长 | | 9 | 傅海曙 | 瑞丽矢美毒事长 | | 10 | (1) 郭振宇 | 贝泰妮青事长 | | | 接单尚明:排名不分先后,围绕专业能力、业绩表现 行业/景 | | | | 响力等维度综合评选得出。 | | 瑞财经 1月28日，由瑞财经推出的"2025年度医疗美容业十大杰出人物"榜单揭晓，华熙生物董事长赵燕 入选。 "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 赵燕，女，1966年7月出生，生物专业本科毕业，理学学士，美国福坦莫大学工商管理硕士。2000年至 2002年任华熙昕宇投资有限公司总经理；自2003年至2019年3月任华熙 ...

Core Viewpoint - Huaxi Bio, a leading company in the biomanufacturing sector, emphasizes the importance of innovation and collaboration among research institutions, enterprises, and government to drive the development of the biomanufacturing industry and achieve market transformation [3][8]. Industry Insights - The competition in the hyaluronic acid market is intensifying, with a focus on technological accumulation and long-term development paths among leading companies [3]. - The industry is shifting from a focus on single products to systemic solutions, highlighting the need for creativity and responsible marketing practices [6]. - The current market is characterized by a lack of innovation, with many companies resorting to imitation rather than developing unique solutions [6]. Talent Development - The biomanufacturing sector requires talent with interdisciplinary knowledge, including biology, engineering, AI, and bioinformatics, to meet the demands of future industry growth [7]. - Attracting creative and self-driven talent in synthetic biology is essential, necessitating a collaborative effort from government, enterprises, and individuals [7]. Policy and Government Role - Beijing has implemented policies to accelerate the innovation and market transformation of the synthetic biology manufacturing industry, demonstrating a strong governmental commitment [8]. - Local initiatives, such as those in Changping District, aim to attract relevant enterprises and talent, creating a multi-layered support system for the industry [8]. Market Transformation Challenges - The main challenge for innovative companies is the effective market transformation of new products, often hindered by strict intellectual property protection and insufficient collaboration mechanisms with research institutions [9]. - A call for government intervention to establish rules and standards for better cooperation between researchers and enterprises is emphasized, aiming to increase the current low conversion rate of research outcomes [9]. AI's Impact on Biomanufacturing - AI is becoming a foundational capability in the biomanufacturing and biotechnology sectors, with companies needing to embrace AI to survive and thrive [10]. - The integration of AI is expected to reshape business logic and organizational structures, potentially leading to exponential growth in the industry [11]. - AI has the potential to bridge the gap between China and developed countries in the biotechnology field, facilitating innovation and enhancing data-driven decision-making [11].

Core Viewpoint - The survival of future enterprises hinges on their ability to truly embrace AI, which is seen as a transformative force in the industry [2][12]. Group 1: Company Overview - Huaxi Biological is a prominent player in the biomanufacturing sector, spanning various fields including active substances, pharmaceuticals, medical aesthetics, functional skincare, and food [2]. - The company has been in the spotlight over the past year, particularly during the Fourth Session of the 14th Beijing Municipal Committee of the Chinese People's Political Consultative Conference [2]. Group 2: Industry Insights - The market for hyaluronic acid and other regenerative materials is becoming increasingly competitive, with a focus on innovation rather than mere imitation [3][5]. - The industry is shifting from single-product offerings to systemic solutions that address consumer needs, emphasizing the importance of scientific backing and social responsibility [5]. Group 3: Talent and Innovation - The transition from manufacturing to creation in biotechnology requires talent with interdisciplinary knowledge, including biology, engineering, AI, and bioinformatics [6][8]. - Attracting creative and self-driven talent in synthetic biology is a collaborative effort involving government, enterprises, and the talent pool itself [8]. Group 4: Policy and Market Transformation - Beijing has implemented policies to accelerate the innovation and market transformation of synthetic biology, demonstrating a strong governmental commitment to this sector [8][9]. - The current bottleneck in innovation lies in the tight control of early-stage intellectual property by academic researchers, which hinders collaboration with enterprises [9]. Group 5: AI's Impact on the Industry - AI is becoming a foundational capability in biomanufacturing, with companies needing to adapt their business logic and organizational structures to survive [10][12]. - The advent of AI is seen as a means to level the playing field in biotechnology, potentially leading to exponential growth through redefined innovation logic [12].